To come to this finding, researchers tracked CLABSIs for one year at a 1,200 bed hospital center. They monitored 209 ICU beds and flagged patients moved to the ICU for a CLABSI contracted in a non-ICU setting.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Of 136 patients and 156 CLABSIs:
- 57 patients were treated for hematological malignancy.
- The device utilization ratio — number of catheter days divided by number of patient days — was 0.27.
- 76 percent of CLABSIs occurred with a tunneled line.
- 21 percent of CLABSIs occurred with a peripherally inserted central catheter.
- Total mortality was 23 percent.
In addition, researchers noted CLABSI rates were significantly higher in non-ICU settings and were associated with significant mortality, with patients treated for HM having the highest mortality.
More Articles on Infection Control & Clinical Quality:
AAMC Releases Guide to Evaluating Public Report Card Quality
Postoperative Pain Control Linked to Patient Satisfaction
ACS’ Online Tool Helps Predict Postoperative Complications
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
